https://biotechmorning.com/news/gilead-arcus-tigit-failure-partnership-unravels Biotech Morning en 2026-04-21T14:10:03.321Z Biotech's $2 Billion Blind Date Just Ended in Tears https://biotechmorning.com/news/lilly-kelonia-7-billion-in-vivo-car-t Biotech Morning en 2026-04-21T14:09:13.777Z Lilly Just Spent $7 Billion to Skip the Hardest Part of Cancer Treatment https://biotechmorning.com/news/replimune-oncolytic-virus-layoffs-fda-rejection Biotech Morning en 2026-04-21T14:08:20.784Z The Virus That Was Supposed to Kill Cancer Just Killed a Company Instead https://biotechmorning.com/news/flagship-serif-biomedicines-modified-dna-launch Biotech Morning en 2026-04-21T14:07:37.061Z Flagship Just Invented a New Type of Drug (No, Seriously) https://biotechmorning.com/news/biogen-850m-tj-biopharma-felzartamab-china-deal Biotech Morning en 2026-04-21T14:06:49.827Z Biogen Just Paid $850M to Own a Drug You've Never Heard Of https://biotechmorning.com/news/odyssey-therapeutics-second-ipo-attempt Biotech Morning en 2026-04-20T14:07:40.639Z The $700M Biotech That Got Rejected by Wall Street Is Back for Round Two https://biotechmorning.com/news/astrazeneca-il33-tozorakimab-phase-3-copd-win Biotech Morning en 2026-04-20T14:07:04.833Z The Drug Target Everyone Gave Up On Just Won Again https://biotechmorning.com/news/novo-nordisk-sickle-cell-disease-etavopivat-phase-3 Biotech Morning en 2026-04-20T14:06:23.243Z Novo Nordisk's Quiet Bet on a Disease That Isn't Obesity